Cargando…

Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil

Serological screening for human T-cell lymphotropic virus type 1 (HTLV-1) is usually performed using enzyme-linked immunosorbent assay (ELISA), particle agglutination, or chemiluminescence assay kits. Due to an antigen matrix improvement entailing the use of new HTLV antigens and changes in the form...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva Brito, Vanessa, Santos, Fred Luciano Neves, Gonçalves, Noilson Lazaro Sousa, Araujo, Thessika Hialla Almeida, Nascimento, Davi Silva Vale, Pereira, Felicidade Mota, Boa-Sorte, Ney Cristian Amaral, Grassi, Maria Fernanda Rios, Caterino-de-Araujo, Adele, Galvão-Castro, Bernardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258847/
https://www.ncbi.nlm.nih.gov/pubmed/30232131
http://dx.doi.org/10.1128/JCM.00961-18
_version_ 1783374569766125568
author da Silva Brito, Vanessa
Santos, Fred Luciano Neves
Gonçalves, Noilson Lazaro Sousa
Araujo, Thessika Hialla Almeida
Nascimento, Davi Silva Vale
Pereira, Felicidade Mota
Boa-Sorte, Ney Cristian Amaral
Grassi, Maria Fernanda Rios
Caterino-de-Araujo, Adele
Galvão-Castro, Bernardo
author_facet da Silva Brito, Vanessa
Santos, Fred Luciano Neves
Gonçalves, Noilson Lazaro Sousa
Araujo, Thessika Hialla Almeida
Nascimento, Davi Silva Vale
Pereira, Felicidade Mota
Boa-Sorte, Ney Cristian Amaral
Grassi, Maria Fernanda Rios
Caterino-de-Araujo, Adele
Galvão-Castro, Bernardo
author_sort da Silva Brito, Vanessa
collection PubMed
description Serological screening for human T-cell lymphotropic virus type 1 (HTLV-1) is usually performed using enzyme-linked immunosorbent assay (ELISA), particle agglutination, or chemiluminescence assay kits. Due to an antigen matrix improvement entailing the use of new HTLV antigens and changes in the format of HTLV screening tests, as well as newly introduced chemiluminescence assays (CLIAs), a systematic evaluation of the accuracy of currently available commercial tests is warranted. We aimed to assess the performance of commercially available screening tests for HTLV infection diagnosis. A diagnostic accuracy study was conducted on a panel of 397 plasma samples: 200 HTLV-negative plasma samples, 170 HTLV-positive plasma samples, and 27 plasma samples indeterminate by Western blotting (WB). WB-indeterminate samples (i.e., those yielding no specific bands for HTLV-1 and/or HTLV-2) were assessed by PCR, and the results were used to compare agreement among the commercially available ELISA screening tests. For performance analysis, WB-indeterminate samples were excluded, resulting in a final study panel of 370 samples. Three ELISA kits (Murex HTLV-1/2 [Murex], anti-HTLV-1/2 SYM Solution [SYM Solution], and Gold ELISA HTLV-1/2 [Gold ELISA]) and one CLIA kit (Architect rHTLV-1/2) were evaluated. All screening tests demonstrated 100% sensitivity. Concerning the HTLV-negative samples, the SYM Solution and Gold ELISA kits had specificity values of >99.5%, while the Architect rHTLV-1/2 test presented 98.1% specificity, followed by Murex, which had a specificity of 92.0%. Regarding the 27 samples with WB-indeterminate results, after PCR confirmation, all ELISA kits showed 100% sensitivity but low specificity. Accuracy findings were corroborated by the use of Cohen's kappa value, which evidenced slight and fair agreement between PCR analysis and ELISAs for HTLV infection diagnosis. Based on the data, we believe that all evaluated tests can be safely used for HTLV infection screening.
format Online
Article
Text
id pubmed-6258847
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-62588472018-12-13 Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil da Silva Brito, Vanessa Santos, Fred Luciano Neves Gonçalves, Noilson Lazaro Sousa Araujo, Thessika Hialla Almeida Nascimento, Davi Silva Vale Pereira, Felicidade Mota Boa-Sorte, Ney Cristian Amaral Grassi, Maria Fernanda Rios Caterino-de-Araujo, Adele Galvão-Castro, Bernardo J Clin Microbiol Immunoassays Serological screening for human T-cell lymphotropic virus type 1 (HTLV-1) is usually performed using enzyme-linked immunosorbent assay (ELISA), particle agglutination, or chemiluminescence assay kits. Due to an antigen matrix improvement entailing the use of new HTLV antigens and changes in the format of HTLV screening tests, as well as newly introduced chemiluminescence assays (CLIAs), a systematic evaluation of the accuracy of currently available commercial tests is warranted. We aimed to assess the performance of commercially available screening tests for HTLV infection diagnosis. A diagnostic accuracy study was conducted on a panel of 397 plasma samples: 200 HTLV-negative plasma samples, 170 HTLV-positive plasma samples, and 27 plasma samples indeterminate by Western blotting (WB). WB-indeterminate samples (i.e., those yielding no specific bands for HTLV-1 and/or HTLV-2) were assessed by PCR, and the results were used to compare agreement among the commercially available ELISA screening tests. For performance analysis, WB-indeterminate samples were excluded, resulting in a final study panel of 370 samples. Three ELISA kits (Murex HTLV-1/2 [Murex], anti-HTLV-1/2 SYM Solution [SYM Solution], and Gold ELISA HTLV-1/2 [Gold ELISA]) and one CLIA kit (Architect rHTLV-1/2) were evaluated. All screening tests demonstrated 100% sensitivity. Concerning the HTLV-negative samples, the SYM Solution and Gold ELISA kits had specificity values of >99.5%, while the Architect rHTLV-1/2 test presented 98.1% specificity, followed by Murex, which had a specificity of 92.0%. Regarding the 27 samples with WB-indeterminate results, after PCR confirmation, all ELISA kits showed 100% sensitivity but low specificity. Accuracy findings were corroborated by the use of Cohen's kappa value, which evidenced slight and fair agreement between PCR analysis and ELISAs for HTLV infection diagnosis. Based on the data, we believe that all evaluated tests can be safely used for HTLV infection screening. American Society for Microbiology 2018-11-27 /pmc/articles/PMC6258847/ /pubmed/30232131 http://dx.doi.org/10.1128/JCM.00961-18 Text en Copyright © 2018 da Silva Brito et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Immunoassays
da Silva Brito, Vanessa
Santos, Fred Luciano Neves
Gonçalves, Noilson Lazaro Sousa
Araujo, Thessika Hialla Almeida
Nascimento, Davi Silva Vale
Pereira, Felicidade Mota
Boa-Sorte, Ney Cristian Amaral
Grassi, Maria Fernanda Rios
Caterino-de-Araujo, Adele
Galvão-Castro, Bernardo
Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil
title Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil
title_full Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil
title_fullStr Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil
title_full_unstemmed Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil
title_short Performance of Commercially Available Serological Screening Tests for Human T-Cell Lymphotropic Virus Infection in Brazil
title_sort performance of commercially available serological screening tests for human t-cell lymphotropic virus infection in brazil
topic Immunoassays
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258847/
https://www.ncbi.nlm.nih.gov/pubmed/30232131
http://dx.doi.org/10.1128/JCM.00961-18
work_keys_str_mv AT dasilvabritovanessa performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil
AT santosfredlucianoneves performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil
AT goncalvesnoilsonlazarosousa performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil
AT araujothessikahiallaalmeida performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil
AT nascimentodavisilvavale performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil
AT pereirafelicidademota performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil
AT boasorteneycristianamaral performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil
AT grassimariafernandarios performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil
AT caterinodearaujoadele performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil
AT galvaocastrobernardo performanceofcommerciallyavailableserologicalscreeningtestsforhumantcelllymphotropicvirusinfectioninbrazil